Amryt trio join Poolbeg leadership team
Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi.
The new recruits include David Allmond, former chief business officer at Amryt, who will take on the same role at Poolbeg from December 1.
Previously, Mr Allmond acquired the distribution rights for Lojuxta (lomitapide) for Europe and the Middle East in 2016. The lipid-lowering agent subsequently became Amryt’s first approved, revenue-generating product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze